Both apicomplexan parasites Toxoplasma gondii and Plasmodium falciparum lack type I NADH dehydrogenases (complex I), but instead encode alternative (type II) NADH dehydrogenases, which are absent in mammalian cells and are thus considered as promising antimicrobial drug targets. The quinolone-like compound 1-hydroxy-2-dodecyl-4(1)quinolone (HDQ) was recently 5 described as a high affinity inhibitor of fungal alternative NADH-dehydrogenases in enzymatic assays, probably by interfering with the ubiquinol binding site of the enzyme. We describe here that HDQ effectively inhibits the replication rate of P. falciparum and T. gondii in tissue culture.
INTRODUCTION
Diseases caused by apicomplexan parasites such as Plasmodium and Toxoplasma are one of the most serious health problems in the world, leading to an estimated 1-3 million deaths per year just due to malaria. The emerging resistance against established drugs in Plasmodium populations 5 emphasizes the need to continuously identify and evaluate novel targets for drug therapy (10, 15) .
A pathway which is well known as an effective drug target against malaria and toxoplasmosis is the mitochondrial electron transport chain (ETC). Several components of the ETC in Plasmodium and Toxoplasma display significant differences compared to their mammalian counterparts, 10 which can be exploited for chemotherapy (4, (23) (24) (25) . Atovaquone is a recently developed antimalarial agent, which inhibits electron transport at the bc1 complex (complex III) by interfering with the ubiquinol oxidation site of cytochrom b (20, 21, 26) . The resulting collapse of the mitochondrial membrane potential (20) is lethal for the parasite.
15
The most fundamental difference in the architecture of the human and Plasmodium electron transport chain consists in the NADH:quinone oxidoreductase activity, which is also called NADH dehydrogenase (2, 8) . Mammals possess a rotenone-sensitive type I NADH dehydrogenase (multi-subunit complex I), which is localized inside the inner mitochondrial membrane. In contrast, genomic data reveal that Plasmodium species and T. gondii lack a 20 complex I, but instead possess an alternative (type II) NADH dehydrogenase(s), which is encoded by a single gene (Pfndh2; accession# PFI0735c) in P. falciparum and two genes in T.
gondii: Tgndh2-I (accession# DQ211932) and Tgndh2-II (accession# DQ228957) (Saleh unpublished data, 8, 9).
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Alternative NADH dehydrogenases are rotenone-insensitive single subunit enzymes and are usually present in the plasma membrane of many bacteria and in the inner mitochondrial membrane of various fungi, plants and some protozoa (11, 14, 17) . The rotenone insensitivity of NADH:quinone oxidoreductase activity in Plasmodium species and in T. gondii was confirmed in biochemical assays (2, 23, 26) . In contrast to type I enzymes, the transfer of electrons from 5 NADH to quinones by alternative NADH dehydrogenases is not coupled with proton translocation. The absence of alternative NADH dehydrogenases in mammalian cells defines these enzymes as promising antimicrobial drug targets. A type II NADH:menaquinone oxidoreductase inhibitor was shown to interfere with Mycobacterium tuberculosis growth (27, 28). In P. falciparum, micromolar concentrations of low affinity flavin reagents were shown to 10 inhibit PfNDH2 activity, to collapse the parasite's mitochondrial membrane potential and to inhibit P. falciparum replication (2).
Recently, the compound 1-hydroxy-2-dodecyl-4(1)quinolone (HDQ) was identified in enzymatic assays as a high affinity inhibitor of the alternative NADH-dehydrogenase from the fungus 15
Yarrowia lipolytica (5) . In this study, we describe that HDQ is a highly effective drug to inhibit replication of P. falciparum and T. gondii in nanomolar concentrations and that it acts in synergism with atovaquone. 
MATERIALS AND METHODS
T. gondii strains and cultivation. Parasites were propagated in human foreskin fibroblasts (HFF) as previously described (18). A clonal isolate of the RH strain was used for quantification of growth rates by immunofluorescence microscopy. A lacZ transfected RH strain (3) was used 5 for beta-galactosidase based quantification of replication rates.
Cultivation of Plasmodium falciparum. The P. falciparum isolate FCBR (16) was cultivated in RPMI 1640 medium supplemented with 10% human plasma and human erythrocytes of blood group A (rhesus positive) as described elsewhere (22) . For maintenance of the culture and for 10 drug susceptibility assays, parasites were cultured in T25 flasks in a total volume of 10 ml. Flasks were flushed with gas composed of 90% nitrogen, 5% O 2 and 5% CO 2 . Cultures were synchronized with the sorbitol method as described elsewhere (12) . (Fig. 1) and all other 1-hydroxy-2-alkyl-4(1)quinolone derivatives were kindly 15 provided by Walter Oettmeier (Ruhr-Universität Bochum, Germany). The derivatives were dissolved in tissue culture grade DMSO at a concentration of 2.5 mM. All further dilutions were performed in tissue culture medium. Atovaquone was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 5 mM. Drug untreated controls of T. gondii and P. falciparum infected cultures were incubated with DMSO in identical concentrations as drug treated samples. Due to the 20 limited amounts of derivatives C 5 , C 6 , C 8 , C 14 , most of the experiments were performed with HDQ. Replication rate determined by beta-galactosidase activity. The beta-galactosidase activity of T. gondii which are stably transfected with the E. coli lacZ gene can be used to accurately quantify the parasite replication rate by using a colorimetric assay (13). Freshly lysed parasites of a beta-galactosidase expressing RH strain (3) were used to infect the HFF monolayer (1x10 4 parasites/well) grown in 24 well plates in 1% DMEM media without phenol red for 4 hours at 15 37° C. The infected monolayers were washed twice with 1% DMEM without phenol red media, and incubated with different concentrations of HDQ in duplicates (1, 0.1, 0.01, and 0.001 µM) and a final concentration of 100 µM CPRG at 37° C. Absorbance at 570 nm and 630 nm was photometrically determined.
Drugs. HDQ

A C C E P T E D
20
Quantification of P. falciparum replication rate using a fluorometric assay. An 800 µl aliquot of a P. falciparum culture was added to 1 ml 0.08% saponin in PBS in order to lyse red blood cells. Subsequent steps of sample preparation were performed as previously described (19) .
Briefly, samples were centrifuged at 15800g for 4 min and the supernatant carefully removed.
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The parasite pellets were solubilized in 25 µl of a solution (pH 5.5) containing 6 M guanidiumHCl and 6 M sodium acetate. Afterwards, 2 ml of a solution containing 2 M NaCl, 50 mM TrisHCl (pH 7.8) and 0.33 µg/ml of Hoechst 33258 was added. Finally, 50 µl of a 24:1 mixture of chloroform-isoamyl alcohol was added and samples were mixed by vortexing. After centrifugation at 15800g for 1 min, 1.9 ml of the supernatant was transferred to 24-well plates. 5
Triplicates of each sample were measured in a fluorometer (Victor 5; Wallac) at wavelengths of 340 and 460 nm. Each well was measured at two different spots. 
RESULTS
HDQ inhibits T. gondii replication.
The quinolone compound HDQ (Fig. 1) was recently shown to inhibit the activity of the mitochondrial alternative (type II) NADH dehydrogenase of the fungus Yarrowia lipolytica in 5 enzymatic assays (5) . We tested the potential of this drug to inhibit the replication of the apicomplexan parasites T. gondii and P. falciparum, which both lack the type I NADH oxidoreductase (complex I), but instead encode alternative NADH dehydrogenases. A confluent monolayer of HFF was infected with tachyzoites of the T. gondii RH-strain and treated with various concentrations of HDQ ranging from 1 nM to 10 µM. Two growth assays were applied to 10 quantify the T. gondii replication rate. First, the average number of parasites per vacuole was determined 24 h post infection by immunofluorescence microscopy. In untreated cells, parasites completed up to four replication cycles, with 58% of vacuoles containing 8 parasites and 22% containing 16 parasites. In contrast, nanomolar concentrations of HDQ were found to effectively inhibit T. gondii replication with a 50% inhibitory concentration (IC 50 ) of 2.4 +/-0.3 nM (Fig.  15   2a) . 90% of the parasites in samples treated with > 10 nM HDQ were located in vacuoles containing only a single parasite, suggesting that the drug is immediately acting on the parasite.
Moreover, immunofluorescence analysis of the intracellular T. gondii treated with 10 µM HDQ showed the presence of abnormal parasites which lost their typical crescent shape (data not shown). Invasion was not inhibited by HDQ, since pretreatment of extracellular parasites with 1-20 1000 nM HDQ for 2 h before infection did not result in a decreased infection rate (data not shown). For the second, independent growth assay, a beta-galactosidase expressing T. gondii RH-strain (3) was used to infect a HFF monolayer and the replication rate was determined 30 h post infection using a colorimetric assay (Fig. 2b) . The replication rate of T. gondii was dose indicating that HDQ in the applied concentrations up to 10 µM has no inhibitory effect on the host cell metabolism .
HDQ inhibits P. falciparum replication. 10
To determine the HDQ susceptibility of P. falciparum, ring stage parasites were cultivated in the presence of HDQ at concentrations of 1 µM, 100 nM, 10 nM and 1 nM for 48 h. As for Toxoplasma gondii, HDQ treatment resulted in a dose dependant decrease of the parasitemia as determined in Giemsa stained blood smears (Fig. 3a) . A reduction of the parasitemia to 50% of the untreated control was achieved at HDQ concentrations of 54 +/-25 nM. To accurately 15 determine the IC 50 of HDQ for P. falciparum, a quantitative growth assay was applied, which is based on the binding of the fluorescence Hoechst 33258 dye to parasite DNA (19) . Cultures of young trophozoites with an initial parasitemia of 2% were incubated for 36 hours in the presence of 1 µM, 100 nM, 10 nM or 1 nM HDQ. 2 µM chloroquine-diphosphate, which at this concentration is completely inhibiting parasite replication, was used as a control to determine the 20 background fluorescence of non-replicating parasites. The fluorescence intensity decreased dosedependently with increasing HDQ concentrations, indicating that parasite replication is effectively inhibited. The IC 50 of HDQ for P. falciparum was determined as 14.0 +/-1.9 nM (Fig.   3b) . Atovaquone is a well established drug to treat Toxoplasmosis and Malaria. We investigated a potential synergistic effect of HDQ with atovaquone on the inhibition of T. gondii replication.
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The combination of both drugs resulted in a stronger inhibition of parasite replication than 5 treatment with the individual drugs (Fig 4) . Synergism was evaluated as the sum of the fractional inhibitory concentrations (sum FIC) by the following equation (1) The length of the alkyl side chain at position 2 is important for drug action. 15 Beside HDQ, which possesses a long hydrophobic (CH 2 ) 11 -CH 3 (C 12 ) side chain at position 2, further 1-hydroxy-2-alkyl-4(1)quinolone derivatives with different alkyl side chain lengths were tested for their ability to inhibit T. gondii replication. Derivatives with alkyl side chains of (CH 2 ) 5 -CH 3 (C 6 ), (CH 2 ) 7 -CH 3 (C 8 ) and (CH 2 ) 13 -CH 3 (C 14 ) inhibited as HDQ (C 12 ) the growth of T. gondii effectively at concentrations of 0.1 µM and 0.01 µM (Fig. 5) . In contrast, a derivative 20 with the alkyl side chain (CH 2 ) 4 -CH 3 (C 5 ) did not inhibit T. gondii replication. This suggests, that the alkyl side chain at position 2 is essential for the inhibitory action of 1-hydroxy-2-alkyl-4(1)quinolone derivatives and needs to have a minimal length of -(CH 2 ) 5 -CH 3 (C 6 ).
Recovery of parasite replication after 24 h of HDQ treatment.
To further characterize the antiparasitic activity of the drug, we incubated T. gondii infected HFF for 24 h with either 0.1 or 1 µM HDQ, followed by cultivation of further 72 h without drug. The ability of the parasites to recover from the drug treatment was then determined by using the number of parasites per parasitophorous vacuole as a parameter for viability. A continuous 5 treatment for 96 h with 0.1 and 1 µM HDQ resulted in an almost complete inhibition of parasite replication in which most parasitophorous vacuoles harbor 1-2 parasites, very rarely a maximum of 4 parasites can be observed, and none of the vacuoles contained 8 or more parasites. For the recovery experiment, a vacuole with 8 parasites was thus considered to contain replicating parasites (Fig. 7) . In samples treated with 0.1 µM HDQ for 24 h, almost 50% of the vacuoles 10 recovered from HDQ treatment. This number increased even to 65.8% when the 24h HDQ treatment started with a delay of 6 h post infection. However, when the HDQ concentration is increased to 1 µM, the recovery strongly decreased to less then 3%, suggesting that at this concentration, a 24 h HDQ treatment exerts a predominately parasiticidal activity. Although it can not completely be ruled out that HDQ has additional effects on T. gondii and P. 10 falciparum which are unrelated to alternative NADH dehydrogenase inhibition, the observed synergism between HDQ and the complex III inhibitor atovaquone suggests, that HDQ as atovaquone affects the mitochondrial electron transport chain. This synergism is most likely due to the inhibition of the ubiquinone/ubiquinol cycle at two different locations, which is the reduction site (alternative NADH dehydrogenase) for HDQ and the oxidation site (complex III) 15 for atovaquone. A synergism of atovaquone with low affinity inhibitors of alternative NADH dehydrogenases was recently shown for Plasmodium falciparum, demonstrating that simultaneous inhibition of the ubiquinone/ubiquinol cycle at different points has a huge pharmacological potential (2). However, the general flavines used in the previous study as diphenylene iodonium chloride have an IC 50 which is 500-fold higher compared to HDQ and are 20 most likely unsuitable for clinical studies (2, 5).
In contrast, the IC 50 of HDQ in the low nanomolar range makes HDQ a highly attractive candidate for further studies, particularly since we did not observe any negative effects on the It has to be mentioned that HDQ in the nanomolar range is not able kill T. gondii, but rather has a static effect on the parasites. Intracellular parasites, which were treated with 10 nM HDQ for 48 h were almost completely able to recover from HDQ mediated growth arrest and to continue 10 replication after drug removal. If the parasites were treated with 10 µM, however, a parasitocidic effect was observed. At this high concentration, which is more than 2000-fold of the IC 50 , side effects of HDQ on targets which are unrelated to the alternative NADH dehydrogenases can not be excluded.
A C C E P T E D
15
A critical feature of the 1-hydroxy-2-alkyl-4(1)quinolone structure is the length of the alkyl side chain at position 2. While derivatives with alkyl side chains of C 6 , C 8 , C 12 (HDQ) and C 14 all displayed excellent anti-parasitic activities in nanomolar ranges, a C 5 derivative completely failed to inhibit T. gondii replication. A minimal alkyl side chain length of C 6 appears thus to be required for drug action. Due to the structural similarities, it is most likely that 1-hydroxy-2-20 alkyl-4(1)quinolones compete with ubiquinones for the same binding site in alternative NADH dehydrogenases (5). However, it has to be mentioned that steady-state inhibition kinetics of HDQ on the Y. lipolytica alternative NADH-dehydrogenase displayed a non-competitive pattern for the hydrophobic ubiquinone derivative DBQ, which the authors of this study used as an electron Sample preparation for the fluorometric assay was performed as previously described (19) . 
